<DOC>
	<DOCNO>NCT01523002</DOCNO>
	<brief_summary>Pyronaridine : artesunate ( Pyramax ) antimalarial fixed-dose combination therapy demonstrate well tolerated effective treatment patient Plasmodium falciparum vivax malaria . This open-label Phase I study two part : drug-drug interaction part intend investigate interaction Pyramax pharmacokinetics CYP2D6 probe metoprolol re-dosing evaluation part intend investigate difference change liver enzymes induced Pyramax first second treatment course effect redo interval change liver enzymes induced Pyramax first second treatment course .</brief_summary>
	<brief_title>Drug Interaction Study Pyronaridine-artesunate Metoprolol Pyronaridine-artesunate Re-dosing Study Healthy Volunteers</brief_title>
	<detailed_description>Healthy subject randomise either arm A ( sequential metoprolol single dose Pyramax 3 day course + metoprolol last day start 7 day Pyramax single dose follow Pyramax redo another 3 day course 90 day later ) arm B ( 2 course 3-days Pyramax separate 60 day ) . Each arm include 22 subject . Subjects follow tolerability pharmacokinetics 42 day follow start Pyramax dosing period . Subjects consider complete study Day 140 ( arm A ) Day 103 ( arm B ) . Any adverse event ongoing time study completion follow resolution unless change expect accord investigator .</detailed_description>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Pyronaridine</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>1 . Male female subject age 18 55 year body weight 50 90 kg body mass index calculate use Quetelet 's Index weight ( kg ) /height2 ( m2 ) 18.530.0 2 . Signed date write informed consent form undergo study related activity 3 . Medically normal subject significant abnormal finding screen physical examination evaluate investigator 4 . Strictly normal value ALT , AST , total bilirubin normal abnormal clinically insignificant result blood urine laboratory parameter screen . 5 . Female subject nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ( i.e. , one year without menses ) undergone sterilization ( via hysterectomy bilateral tubal ligation ) 6 . Female subject childbearing potential negative urine pregnancy test screening confirm Day 1 serum pregnancy test agree one follow method : Double barrier method contraception 2 week first study drug administration throughout entire study follow period Partner ( ) undergo vasectomy negative sperm least 6 month 7 . The ability understand requirement study willingness comply study procedures 1 . Known history evidence clinically significant disorder cardiovascular ( include arrhythmia , acute QTc interval great equal 450 mseconds ) , respiratory ( include active tuberculosis ) , hepatic , renal , gastrointestinal , immunological ( include active HIVAIDS ) , neurological ( include auditory ) , endocrine , infectious , malignancy , psychiatric abnormality ( include head trauma ) 2 . Known history hypersensitivity , allergic adverse reaction pyronaridine artesunate artemisinins metoprolol . 3 . Other contraindication pyronaridine use 4 . Other contraindication metoprolol use include second third degree atrioventricular block , heart rate 50 beat per minute , uncompensated heart failure need treatment inotropic agent , clinically apparent hypotension , sinus bradycardia sick sinus syndrome , peripheral arterial disease , pheochromocytoma , asthma , chronic obstructive pulmonary disease , depression condition opinion Investigator may worsen administration metoprolol . 5 . Known active Hepatitis A IgM ( HAVIgM ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV Ab ) 6 . Seropositive HIV antibody 7 . Previous participation clinical study pyronaridine : artesunate ( Pyramax ) 8 . Presence recent history ( last two year ) tobacco abuse ( â‰¥10 cigarettes/day ) 9 . Known suspected alcohol abuse illicit drug use 10 year study start positive finding urine drug screen 10 . Intake alcoholic beverage within 72 hour study drug administration caffeinecontaining food beverage , coffee , tea , chocolate , cola , 48 hour study drug administration 11 . Gilbert 's disease 12 . Administration systemic medication herbal product within 14 day first dose study drug . If investigator considers specific product would interfere safety subject objective study , topical treatment well vitamins mineral supplement contain substance allow 4 day dose . Ibuprofen dose 1200 mg per day 3 consecutive day 6 nonconsecutive day allow 24h first dose study drug . 13 . Plasma donation 3 month study start 14 . Blood donation 500 mL 3 month study start 15 . Participation clinical study last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>